Your Weekly Dose of News in Pharma, Biotech and Health
In the healthcare spotlight, Carl June stands as a pioneer with his groundbreaking work on a 'universal CAR-T' therapy, potentially reshaping cancer treatment. Simultaneously, an industry-backed film sheds light on the looming global threat of antimicrobial resistance, underlining the urgent need for collaborative efforts to address this crisis. Meanwhile, Novo Nordisk's ascent to Europe's most valuable pharmaceutical company demonstrates the dynamic nature of healthcare markets, signifying significant shifts in industry value.
Image Credit: BBC Storyworks via YouTube
Biotech
The 10 highest value R&D projects in biopharma
Handful of biotechs expected to IPO this fall, but many are stuck in ‘holding pattern’ until 2024
Health
5 names to know at Facebook: the people behind its push into health care
Pharma
The world will need to stop piggybacking on US pharma
Global threat of antibiotic resistance highlighted in new film supported by Pfizer, MSD, Shionogi and AMR Action Fund
Pharma industry reputation settles into ‘new normal’ after goodwill from insulin price drop fades
Weight-loss drug maker Novo Nordisk becomes Europe’s most valuable company`
Marketing
Reshaping biopharma marketing with point-of-care messaging
Research
Carl June unveils a plan for a ‘universal CAR-T’
3D-printed tumors: startup hopes to drive cancer drug discovery
For an overview of previous Weekly Notables, visit our Archive